Receptor Drug Reduces Memory Loss, Oxidative Stress in Alzheimer’s Disease
Research presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics discussed a chemical that binds to endothelin B receptors used to treat Alzheimer’s disease in rats, which may be able to halt the disease from progressing. Using endothelin B receptors via intravenous injection of IRL-1620 (a chemical that binds to endothelin B receptors) to attempt to prevent and repair the damage to the brain caused by Alzheimer’s disease, researchers found that treatment with IRL-1620 reversed some effects. “Intravenous injection with the drug improved memory deficit by 50 to 60 percent and reduced oxidative stress by 45 to 50 percent,” one of the study’s co-authors explained. “We also found that treatment with IRL-1620 enhanced certain recovery processes within the AD-damaged brain, resulting in more new blood vessels and neuronal cells. This indicates reparative processes occurring in the damaged brain.” To read more about this study, click here.
Microsurgery Course Zurich
March 29-April 1, 2017; Zurich, Switzerland
12th World Congress on Brain Injury
March 29-April 1, 2017; New Orleans
2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.
Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany
Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.